Scholar Rock advances apitegromab FDA review
Scholar Rock (NASDAQ:SRRK) removed Catalent Indiana as a commercial fill-finish facility from its apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA), with FDA review continuing using an alternate facility.










